As part of the ongoing effort to address the opioid addiction and overdose crisis in the U.S., a group of state attorneys general and the companies involved in a possible $26 billion settlement with opioid producers laid out key details of the settlement on Wednesday. The deal calls for the drugmaker Johnson & Johnson to pay up to $5 billion, in addition to billions more from the major national drug distribution companies. AmerisourceBergen and Cardinal Health are each to contribute $6.4 billion. McKesson is to pay $7.9 billion. States – except West Virginia, which has already settled with the companies – will have 30 days to approve the agreements. After that, local governments will have four months to sign on. Each company will decide whether enough jurisdictions agree to the deal to move ahead with it. “While the companies strongly dispute the allegations made in these lawsuits, they believe the proposed settlement agreement and settlement process it establishes … are important steps toward achieving broad resolution of governmental opioid claims and delivering meaningful relief to communities across the United States,” the distribution companies said in a statement. Purdue Pharma:Sackler family moves closer to OxyContin bankruptcy settlement Not just a ‘white problem’:Blacks and Latinos see largest spike in overdose deaths during COVID-19 pandemic, study finds
Joshua Sharfstein, a vice dean at the Johns Hopkins Bloomberg School of Public Health, said it’s crucial that the money is spent to combat the opioid scourge because the overdose epidemic is raging.
Overdoses during COVID-19:Overdose deaths hit record number in US in 2020 amid pandemic
Opioid crisis:Johnson & Johnson agrees to pay $230M to settle New York case
Last year, there were a record 93,000 fatal overdoses from all drugs in the U.S. The majority of them involved fentanyl, a potent synthetic opioid that has medical uses but is also produced illicitly.
“Everybody is both excited and a little worried,” Sharfstein said of the expected funds, “a little worried that they may be squandered.”
Another concern is that some government officials have been too busy dealing with the coronavirus to fully consider where the settlement funds should go.
“I’m afraid that in some places, there just may not be a lot of attention (paid to it), and it could get put back into the general fund,” said Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officials. “It’s not that there aren’t some people out there doing it. But leadership is having a hard time engaging in this because they’re so caught up in the pandemic.”
Bradley D. Stein, director of the RAND Corporation’s Opioid Policy Center, said it’s important to spend the money on efforts that are proven to be effective, including treating addictions and using drugs to stop overdoses.
“We know treatment works,” he said. “We know naloxone appears to be very important in preventing overdose deaths. … There’s not going to be a silver bullet. It may vary, community by community.”